BioCryst Pharmaceuticals ... (BCRX)
NASDAQ: BCRX
· Real-Time Price · USD
10.36
-0.04 (-0.38%)
At close: Jun 13, 2025, 3:59 PM
10.68
3.12%
After-hours: Jun 13, 2025, 04:48 PM EDT
BioCryst Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2019 |
|---|---|---|---|---|
| Collaborative And Other Research And Development Revenue | 8.04M | 6.72M | 267.71M | 17.53M |
| Collaborative And Other Research And Development Revenue Growth | +19.77% | -97.49% | +1426.89% | n/a |
| Product Revenue | 442.67M | 324.7M | 214K | n/a |
| Product Revenue Growth | +36.33% | +151627.10% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 82.47M | 80.47M | 65.08M | 61.21M | 59.36M | 64.38M | 50.65M | 51M | 47.87M | 50.15M | 36.92M | 38.02M | 34.28M | 35.39M | 34.99M | 26.32M | 22.11M | 20.99M | 17.2M | 13.88M | 15.87M | 10.49M | 11.73M | 8.66M | 6.24M | 4.49M | 7.92M | 9.49M | 7.61M | 4.7M | 3.34M | 2.83M | 3.06M | 2.56M | 2.76M | 2.72M | 3.21M | 2.72M | 2.73M | 3.53M | 4.06M |
| Selling, General, and Administrative Revenue Growth | +2.48% | +23.64% | +6.32% | +3.12% | -7.79% | +27.12% | -0.68% | +6.54% | -4.56% | +35.85% | -2.89% | +10.89% | -3.12% | +1.13% | +32.92% | +19.04% | +5.38% | +22.05% | +23.86% | -12.49% | +51.25% | -10.62% | +35.52% | +38.81% | +38.93% | -43.33% | -16.53% | +24.75% | +61.96% | +40.53% | +17.96% | -7.33% | +19.41% | -7.08% | +1.17% | -15.19% | +18.04% | -0.37% | -22.72% | -12.98% | n/a |
| Research and Development Revenue | 37.27M | 49.44M | 41.08M | 37.62M | 46.49M | 70.05M | 46.88M | 51.25M | 48.39M | 73.21M | 52.74M | 61.99M | 65.36M | 63.53M | 49.97M | 52.87M | 42.44M | 35.35M | 30.25M | 27.5M | 29.87M | 26.77M | 25.12M | 27.68M | 27.49M | 23.43M | 22.01M | 21.01M | 18.44M | 16.92M | 17.51M | 15.76M | 16.77M | 12.16M | 14.11M | 14.17M | 20.58M | 19.05M | 20.07M | 16.52M | 17.12M |
| Research and Development Revenue Growth | -24.62% | +20.35% | +9.19% | -19.08% | -33.63% | +49.43% | -8.52% | +5.91% | -33.90% | +38.81% | -14.92% | -5.16% | +2.88% | +27.13% | -5.49% | +24.60% | +20.03% | +16.89% | +9.99% | -7.93% | +11.55% | +6.58% | -9.25% | +0.68% | +17.34% | +6.48% | +4.74% | +13.93% | +8.96% | -3.34% | +11.10% | -6.03% | +37.93% | -13.80% | -0.43% | -31.16% | +8.04% | -5.08% | +21.44% | -3.48% | n/a |